Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- Trust, access confer success in community-based hypertension management
-
- Gaps in CV care of the cancer survivor Steven Philips, MD, PhD; Vlad G. Zaha, MD, PhD; Javid J. Moslehi, MD
- Combination therapy for hypertension, osteoarthritis receives FDA green light
- FDA approves less-invasive LVAD for advanced HF
- FDA OKs next-generation device for transcatheter mitral valve repair
- Panel favors approval of new AAA stent graft system
- New technologies continue to emerge for treatment of arrhythmias
- Cardiac MRI identifies nonobstructive disease, diagnoses microvascular angina
- Global burden of HIV-related CVD on the rise
-
- Low-dose rivaroxaban may improve net clinical outcomes in ACS
- MI risk lower with direct oral anticoagulants vs. vitamin K antagonists
- Multivitamins, minerals fail to improve CV outcomes
- Oral ibuprofen boosts patent ductus arteriosus closure in preterm infants
- Review: 'Little, if any, clinical reason' to use ACE inhibitors for hypertension
- USPSTF: Insufficient evidence regarding benefits, harms of ankle-brachial index for PAD, CVD risk
- VIDEO: Vascular injury in Afghanistan conflict spotlighted
- Alirocumab plus statin cuts cardiac events in patients with diabetes, ACS
-
- Ambulatory hemodynamic sensor reduces risk for HF hospitalization, mortality
- Consider patient risk when targeting BP in diabetes
- Consumer technology poised to improve diabetes, CVD management
- Most adults with diabetes, CVD do not meet secondary prevention targets
- OBSERVE-4D: No amputation risk with canagliflozin in type 2 diabetes
- VIDEO: Newer diabetes agents join cardiologists' arsenal
- Trial Scorecard: CAABL-AF
- Trial Scorecard: CHAMP-HF
-
- Trial Scorecard: ERIS
- Trial Scorecard: MERCURY PE
- Trial Scorecard: OBSERVE-4D
- Trial Scorecard: PARAMEDIC2
- Trial Scorecard: PROACT
- Trial Scorecard: TROFI II